Policy & Regulation

Adaptive licensing: A new approach for drug approvals

Read more

IMI: As Big Pharma pulls back, IMI steps in

Read more

MRC Technology: Going global for local returns

Read more

EU Transparency Directive: changes afoot on pricing and reimbursement

Read more

How to strengthen the biopharma ecosystem

Read more

Planning for the Unified Patent Court

Read more

An analysis of accelerated approval for cancer drugs

Read more

Avastin vs Lucentis: the drug reimbursement dilemma of the century

Read more

EU pharmacovigilance law comes into force

Read more

Commentary on the impact of pharmacovigilance legislation

Read more